IQVIA Holdings Inc (IQV)vsNatera Inc (NTRA)
IQV
IQVIA Holdings Inc
$258.44
-3.33%
HEALTHCARE · Cap: $45.35B
NTRA
Natera Inc
$378.92
-8.54%
HEALTHCARE · Cap: $61.18B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 539% more annual revenue ($17.31B vs $2.71B). IQV leads profitability with a 8.1% profit margin vs -7.1%. IQV earns a higher WallStSmart Score of 59/100 (C).
IQV
Buy59
out of 100
Grade: C
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.7%
Fair Value
$205.31
Current Price
$258.44
$53.13 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Revenue surging 37.7% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
0.0% earnings growth
Weak financial health signals
Trading at 29.9x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Market Cap, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
IQV profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.50 — expect wider price swings.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (59/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?